Business
INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting
Data on Neuroinflammation and Alzheimer’s Disease to be Presented by Dr. Malú Tansey; Presentation Selected for Meeting’s Press Conference LA JOLLA, Calif.,
About this update from Inmune Bio Inc.
[{"type":"text","content":" \n Data on Neuroinflammation and Alzheimer’s Disease to be Presented by Dr. Malú Tansey; Presentation Selected for Meeting’s Press Conference LA JOLLA, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatments that harness the patient’s innate immune system to fight disease, announced today a poster presentation related to the company’s program in Alzheimer’s disease at the upcoming Society for Neuroscience (SfN) 49th Annual Meeting, to be held Oct. 19–23 at McCormick Place in Chicago. In addition, INmune Bio announced that this presentation has been selected for presentation during the meeting’s press conference. Presented in a poster by Malú Tansey, Ph.D., Professor of Neuroscience and Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida College of Medicine, the data from studies involving the use of INmune Bio’s XPro1595 demonstrate the critical role of the immune system on an individual's genetic risk in the context of environmental exposures, such as a diet high in fat and sugar, for neurodegenerative diseases such as Alzheimer’s. The Company believes that XPro1595 is a next generation anti-inflammatory that crosses the blood-brain barrier to affect neurodegenerative diseases by selectively inhibiting soluble tumor necrosis factor. “It’s become clear that neurological disorders can arise from or be exacerbated by innate immune dysfunction and chronic inflammation resulting from both genetic and environmental factors such as diet,” said Dr. Tansey. “Harnessing the power of the immune system could potentially delay or perhaps even prevent some of these neurological disorders. Our results provide a compelling rationale for moving forward with a clinical trial in early Alzheimer’s disease patients.” The SfN Annual Meeting is the premier venue for neuroscientists to present emerging science, learn from experts, forge collaborations with peers and explore new tools and technologies related to the brain and the nervous system. Poster Details Session: Alzheimer's Disease and Other Dementias: Therapeutic Strategies III Poster number: 564 Presentation Title: Soluble tnf mediates obesogenic diet‑induced alterations in peripheral and brain immunophenotype in a model of Alzheimer's disease Time and Date: 1:00 PM, Oct. ...